+

WO1999043654A3 - Inhibiteurs d'enzymes phospholipases - Google Patents

Inhibiteurs d'enzymes phospholipases Download PDF

Info

Publication number
WO1999043654A3
WO1999043654A3 PCT/US1999/003898 US9903898W WO9943654A3 WO 1999043654 A3 WO1999043654 A3 WO 1999043654A3 US 9903898 W US9903898 W US 9903898W WO 9943654 A3 WO9943654 A3 WO 9943654A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
phospholipase enzymes
compounds
mammal
administration
Prior art date
Application number
PCT/US1999/003898
Other languages
English (en)
Other versions
WO1999043654A2 (fr
Inventor
Jasbir S Seehra
John C Mckew
Frank Lovering
Jean E Bemis
Yibin Xiang
Lihren Chen
John L Knopf
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200000871A priority Critical patent/EA003876B1/ru
Priority to AU27825/99A priority patent/AU765427B2/en
Priority to JP2000533412A priority patent/JP2002504541A/ja
Priority to HU0101146A priority patent/HUP0101146A3/hu
Priority to EP99908378A priority patent/EP1062205A2/fr
Priority to KR1020007009457A priority patent/KR20010041344A/ko
Priority to EEP200000488A priority patent/EE200000488A/xx
Priority to NZ506329A priority patent/NZ506329A/xx
Priority to BR9908275-6A priority patent/BR9908275A/pt
Application filed by Genetics Inst filed Critical Genetics Inst
Priority to SK1275-2000A priority patent/SK12752000A3/sk
Priority to CA002322162A priority patent/CA2322162A1/fr
Priority to IL13771999A priority patent/IL137719A0/xx
Publication of WO1999043654A2 publication Critical patent/WO1999043654A2/fr
Publication of WO1999043654A3 publication Critical patent/WO1999043654A3/fr
Priority to NO20004219A priority patent/NO20004219L/no
Priority to HR20000551A priority patent/HRP20000551A2/hr
Priority to BG104779A priority patent/BG104779A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des composés et des compositions pharmaceutiques qui conviennent pour le traitement ou la prévention d'affections inflammatoires chez un mammifère. Elle concerne des procédés qui consistent à administrer de nouveaux composés pharmaceutiquement efficaces de la formule (I) ou (II), ou des sels pharmaceutiquement acceptables desdits composés. Dans ladite formule, R1-R5 sont tels que définis dans le mémorandum descriptif.
PCT/US1999/003898 1998-02-25 1999-02-24 Inhibiteurs d'enzymes phospholipases WO1999043654A2 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
BR9908275-6A BR9908275A (pt) 1998-02-25 1999-02-24 Inibidores de enzimas fosfolipase
JP2000533412A JP2002504541A (ja) 1998-02-25 1999-02-24 ホスホリパーゼ酵素阻害剤
HU0101146A HUP0101146A3 (en) 1998-02-25 1999-02-24 Indole derivatives as inhibitors of phospholipase enzymes and pharmaceutical compositions containing them
EP99908378A EP1062205A2 (fr) 1998-02-25 1999-02-24 Inhibiteurs d'enzymes phospholipases
KR1020007009457A KR20010041344A (ko) 1998-02-25 1999-02-24 포스포리파제 효소의 억제제
EEP200000488A EE200000488A (et) 1998-02-25 1999-02-24 Fosfolipaasensüümide inhibiitorid ja farmatseutilised kompositsioonid
NZ506329A NZ506329A (en) 1998-02-25 1999-02-24 Inhibitors of phospholipase enzymes
EA200000871A EA003876B1 (ru) 1998-02-25 1999-02-24 Ингибиторы фосфолипазных ферментов
SK1275-2000A SK12752000A3 (sk) 1998-02-25 1999-02-24 Inhibítory fosfolipázových enzýmov, farmaceutický prostriedok s ich obsahom a ich použitie
AU27825/99A AU765427B2 (en) 1998-02-25 1999-02-24 Inhibitors of phospholipase enzymes
CA002322162A CA2322162A1 (fr) 1998-02-25 1999-02-24 Inhibiteurs d'enzymes phospholipases
IL13771999A IL137719A0 (en) 1998-02-25 1999-02-24 Inhibitors of phospholipase enzymes
NO20004219A NO20004219L (no) 1998-02-25 2000-08-23 Inhibitorer av fosfolipaseenzymer
HR20000551A HRP20000551A2 (en) 1998-02-25 2000-08-24 Inhibitors of phospholipase enzymes
BG104779A BG104779A (en) 1998-02-25 2000-09-19 Inhibitors of phospholipase enzymes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3059298A 1998-02-25 1998-02-25
US09/030,592 1998-02-25

Publications (2)

Publication Number Publication Date
WO1999043654A2 WO1999043654A2 (fr) 1999-09-02
WO1999043654A3 true WO1999043654A3 (fr) 1999-10-28

Family

ID=21854952

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/003898 WO1999043654A2 (fr) 1998-02-25 1999-02-24 Inhibiteurs d'enzymes phospholipases

Country Status (21)

Country Link
EP (1) EP1062205A2 (fr)
JP (1) JP2002504541A (fr)
KR (1) KR20010041344A (fr)
CN (1) CN1310706A (fr)
AU (1) AU765427B2 (fr)
BG (1) BG104779A (fr)
BR (1) BR9908275A (fr)
CA (1) CA2322162A1 (fr)
EA (1) EA003876B1 (fr)
EE (1) EE200000488A (fr)
GE (1) GEP20032920B (fr)
HR (1) HRP20000551A2 (fr)
HU (1) HUP0101146A3 (fr)
ID (1) ID26250A (fr)
IL (1) IL137719A0 (fr)
NO (1) NO20004219L (fr)
NZ (1) NZ506329A (fr)
PL (1) PL343007A1 (fr)
SK (1) SK12752000A3 (fr)
TR (1) TR200002447T2 (fr)
WO (1) WO1999043654A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US8969344B2 (en) 2005-08-02 2015-03-03 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US9006256B2 (en) 2006-05-18 2015-04-14 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
US9504746B2 (en) 2004-09-17 2016-11-29 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19917504A1 (de) * 1999-04-17 2000-10-19 Dresden Arzneimittel Verwendung von Hydroxyindolen, die Inhibitoren der Phosphodiesterase 4 sind, zur Therapie chronisch obstruktiver Lungenerkrankungen
PL343708A1 (en) * 1998-05-01 2001-08-27 Lilly Co Eli Spla2
TWI269654B (en) * 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
DE19963178A1 (de) * 1999-12-27 2001-07-05 Gruenenthal Gmbh Substituierte Indol-Mannichbasen
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
AUPQ876400A0 (en) * 2000-07-14 2000-08-03 University Of Queensland, The Compositions and method of using them
ATE362468T1 (de) 2000-07-25 2007-06-15 Merck & Co Inc N-substituierte indole mit anwendung in der behandlung von diabetes
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
DK1415987T3 (da) 2000-10-20 2007-07-02 Eisai R&D Man Co Ltd Nitrogenholdige aromatiske ringforbindelser til anvendelse som midler mod cancer
DE60135579D1 (de) 2000-11-02 2008-10-09 Us Gov Health & Human Serv Wirkstoffe für die verminderung von amyloid precursor protein und die behandlung von schwachsinn, und deren verfahren der verwendung
ES2290318T3 (es) * 2001-06-20 2008-02-16 Wyeth Derivados sustituidos de acido indolico como inhibidores del inhibidor del activador del plasminogeno-1 (pai-1).
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
EP1844771A3 (fr) * 2001-06-20 2007-11-07 Wyeth Dérives d'acide indole substitue utilises en tant qu'inhibiteurs de l'inhibiteur-1 (PAI-1) de l'activateur plasminogene
CA2452743A1 (fr) 2001-08-03 2003-02-13 Pharmacia & Upjohn Company 5-arylsulfonyl indoles presentant une affinite avec les recepteurs 5-ht6
AU2002323474B2 (en) 2001-09-13 2006-10-05 Synta Pharmaceuticals Corp 3-glyoxlylamideindoles for treating cancer
US6797708B2 (en) 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
AU2002351182B2 (en) * 2001-12-03 2009-01-15 Novartis Ag Inhibitors of cytosolic phospholipase A2
US7101875B2 (en) 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US6984735B2 (en) 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US6635771B2 (en) 2001-12-03 2003-10-21 Wyeth N-benzhydryl indole compounds
JP2005526831A (ja) * 2002-04-09 2005-09-08 アステックス テクノロジー リミテッド 医薬化合物
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
WO2004019869A2 (fr) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles presentant un effet antidiabetique
WO2004020409A1 (fr) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles a activite antidiabetique
US7348351B2 (en) 2002-12-10 2008-03-25 Wyeth Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
EP1569900B1 (fr) 2002-12-10 2006-06-28 Wyeth Derives substitues d'acides 3-carbonyl- indol-1-yl acetique comme inhibiteurs-1dd'activation plasminogenique
DE60327550D1 (de) 2002-12-10 2009-06-18 Wyeth Corp Substituierte indoloxoacetylaminoessigsäurederivate als inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
DK1569901T3 (da) 2002-12-10 2009-02-16 Wyeth Corp Aryl-, aryloxy- og alkoxysubstituerede 1H-indol-3-yl-glyoxylsyrederivater som inhibitorer af plasminogenaktivatorinhibitor-1 (PAI-1)
US7129264B2 (en) * 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
CA2570363A1 (fr) 2004-06-18 2005-12-29 Biolipox Ab Indoles utilises dans le traitement d'inflammations
WO2006023865A1 (fr) 2004-08-23 2006-03-02 Wyeth Acides d'oxazolo-naphthyl utilises en tant modulateurs de l'inhibiteur de type-1 (pai-1) de l'activateur de plasminogene utiles dans le traitement de la thrombose et des maladies cardio-vasculaires
BRPI0514572A (pt) 2004-08-23 2008-06-17 Wyeth Corp ácidos de tiazolo-naftila
BRPI0514549A (pt) 2004-08-23 2008-06-17 Wyeth Corp ácidos de pirrol-naftila como inibidores de pai-1
ATE501119T1 (de) 2005-01-19 2011-03-15 Biolipox Ab Entzündungshemmende indol-derivate
WO2007024294A2 (fr) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certains urees substitues, modulateurs de l'activite des kinases
TW200718687A (en) * 2005-05-27 2007-05-16 Wyeth Corp Inhibitors of cytosolic phospholipase A2
US7683091B2 (en) 2005-08-17 2010-03-23 Wyeth Substituted indoles and methods of their use
GB0525141D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
AU2007206016A1 (en) 2006-01-13 2007-07-26 Wyeth Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
UA94600C2 (en) 2006-01-24 2011-05-25 Эли Лилли Энд Компани Indole sulfonamide modulators of progesterone receptors
US20070185186A1 (en) * 2006-02-03 2007-08-09 Wyeth Compositions for the delivery of substituted napthyl indole derivatives and methods of their use
NZ596024A (en) 2006-08-07 2013-07-26 Ironwood Pharmaceuticals Inc Indole compounds
ME00681B (fr) * 2006-10-19 2011-12-20 Takeda Pharmaceuticals Co Compose indole
RU2485102C2 (ru) 2008-01-31 2013-06-20 Санофи-Авентис Циклические индол-3-карбоксамиды, их получение и их применение в качестве лекарственных препаратов
AU2009241038B2 (en) 2008-04-28 2011-12-22 Asahi Kasei Pharma Corporation Phenylpropionic acid derivative and use thereof
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
US8889730B2 (en) * 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
AU2014266223B2 (en) 2013-05-14 2020-06-25 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
WO2016031841A1 (fr) 2014-08-28 2016-03-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 Dérivé de quinoline de pureté élevée et son procédé de fabrication
CN107427505A (zh) 2015-02-25 2017-12-01 卫材R&D管理有限公司 用于抑制喹啉衍生物的苦味的方法
KR20250020678A (ko) 2015-03-04 2025-02-11 머크 샤프 앤드 돔 엘엘씨 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
EP3338779B1 (fr) 2015-08-20 2021-06-30 Eisai R&D Management Co., Ltd. Combinaison de lenvatinib avec etoposide et ifosfamide pour utilisation dans le traitement d'un tumeur
JP6872195B2 (ja) * 2015-10-29 2021-05-19 国立大学法人東北大学 コラーゲン産生抑制剤
CN106810488B (zh) * 2015-11-27 2021-02-19 中国科学院上海药物研究所 一类用作GPR17和CysLT1双重拮抗剂的化合物、其制备方法和用途
CA3061888A1 (fr) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Traitement du carcinome hepatocellulaire
CN108530354B (zh) * 2018-05-07 2019-12-10 青岛农业大学 一种含苯磺酰基喹啉类化合物的合成方法
FI3860998T3 (fi) 2018-10-05 2024-03-27 Annapurna Bio Inc Yhdisteitä ja koostumuksia apj-reseptorin aktiivisuuteen liittyvien tautitilojen hoitoon

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3271416A (en) * 1961-10-24 1966-09-06 Merck & Co Inc Indolyl aliphatic acids
FR1583552A (fr) * 1967-04-11 1969-11-14
CH484111A (fr) * 1966-04-12 1970-01-15 Sumitomo Chemical Co Procédé pour préparer de nouveaux dérivés de l'acide aliphatique N-benzoyl-3-indolylique
US3629284A (en) * 1965-04-19 1971-12-21 Sumitomo Chemical Co Process for the preparation of 3-indolyl aliphatic acid derivatives
FR2152377A1 (en) * 1971-09-09 1973-04-27 Sumitomo Chemical Co 1-phenyl-2-methyl-5-alkyl or alkoxy-3-indolylacetic acid - derivs - antiinflammatory, analgesic, antipyretic
FR2158464A1 (fr) * 1971-11-03 1973-06-15 Ici Ltd
EP0337767A1 (fr) * 1988-04-13 1989-10-18 Ici Americas Inc. Amides cycliques
EP0337766A1 (fr) * 1988-04-14 1989-10-18 Ici Americas Inc. Carboxamides hétéra-aliphatiques
US4894386A (en) * 1987-04-15 1990-01-16 Ici Americas Inc. Aliphatic carboxamides
WO1992003132A1 (fr) * 1990-08-20 1992-03-05 Abbott Laboratories Derives d'indole inhibant la biosynthese de leucotriene
EP0620214A1 (fr) * 1993-04-16 1994-10-19 Eli Lilly And Company Hydrazide de l'acide 1H-indole-3-acétique comme inhibiteurs de sPLA2
EP0620215A1 (fr) * 1993-04-16 1994-10-19 Eli Lilly And Company Dérivés de 1H-idole-3-acétamide comme inhibiteurs de sPLA2
WO1995013266A1 (fr) * 1993-11-12 1995-05-18 Merckle Gmbh Chem.-Pharm. Fabrik Acides acylpyrrole-alcanoiques et indole-2-alcanoiques et leurs derives utilises comme inhibiteurs de la phospholipase a¿2?
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
EP0675110A1 (fr) * 1994-04-01 1995-10-04 Eli Lilly And Company 1H-Indole-3-glyoxylamide sPLA2 inhibiteurs
WO1996037467A1 (fr) * 1995-05-22 1996-11-28 Merck Frosst Canada Inc. Derives d'acide n-benzylindol-3-ylbutanoique en tant qu'inhibiteurs de la cyclooxygenase-2
WO1996037469A1 (fr) * 1995-05-22 1996-11-28 Merck Frosst Canada Inc. Derives de l'acide n-benzylindole-3-yl propanique inhibiteurs de la cyclooxygenase-2
WO1997013751A1 (fr) * 1995-10-10 1997-04-17 Pfizer Inc. Indole-carbamates comme antagonistes de leukotriene
WO1998005637A1 (fr) * 1996-08-01 1998-02-12 Merckle Gmbh Acides acylpyrroldicarboxyliques et acides acylindoldicarboxyliques et leurs derives utilises en tant qu'inhibiteurs de la phospholipase a2 cytosolique
WO1998008818A1 (fr) * 1996-08-26 1998-03-05 Genetics Institute, Inc. Inhibiteurs des enzymes phospholipases

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3271416A (en) * 1961-10-24 1966-09-06 Merck & Co Inc Indolyl aliphatic acids
US3629284A (en) * 1965-04-19 1971-12-21 Sumitomo Chemical Co Process for the preparation of 3-indolyl aliphatic acid derivatives
CH484111A (fr) * 1966-04-12 1970-01-15 Sumitomo Chemical Co Procédé pour préparer de nouveaux dérivés de l'acide aliphatique N-benzoyl-3-indolylique
FR1583552A (fr) * 1967-04-11 1969-11-14
FR2152377A1 (en) * 1971-09-09 1973-04-27 Sumitomo Chemical Co 1-phenyl-2-methyl-5-alkyl or alkoxy-3-indolylacetic acid - derivs - antiinflammatory, analgesic, antipyretic
FR2158464A1 (fr) * 1971-11-03 1973-06-15 Ici Ltd
US4894386A (en) * 1987-04-15 1990-01-16 Ici Americas Inc. Aliphatic carboxamides
EP0337767A1 (fr) * 1988-04-13 1989-10-18 Ici Americas Inc. Amides cycliques
EP0337766A1 (fr) * 1988-04-14 1989-10-18 Ici Americas Inc. Carboxamides hétéra-aliphatiques
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
WO1992003132A1 (fr) * 1990-08-20 1992-03-05 Abbott Laboratories Derives d'indole inhibant la biosynthese de leucotriene
EP0620214A1 (fr) * 1993-04-16 1994-10-19 Eli Lilly And Company Hydrazide de l'acide 1H-indole-3-acétique comme inhibiteurs de sPLA2
EP0620215A1 (fr) * 1993-04-16 1994-10-19 Eli Lilly And Company Dérivés de 1H-idole-3-acétamide comme inhibiteurs de sPLA2
WO1995013266A1 (fr) * 1993-11-12 1995-05-18 Merckle Gmbh Chem.-Pharm. Fabrik Acides acylpyrrole-alcanoiques et indole-2-alcanoiques et leurs derives utilises comme inhibiteurs de la phospholipase a¿2?
EP0675110A1 (fr) * 1994-04-01 1995-10-04 Eli Lilly And Company 1H-Indole-3-glyoxylamide sPLA2 inhibiteurs
WO1996037467A1 (fr) * 1995-05-22 1996-11-28 Merck Frosst Canada Inc. Derives d'acide n-benzylindol-3-ylbutanoique en tant qu'inhibiteurs de la cyclooxygenase-2
WO1996037469A1 (fr) * 1995-05-22 1996-11-28 Merck Frosst Canada Inc. Derives de l'acide n-benzylindole-3-yl propanique inhibiteurs de la cyclooxygenase-2
WO1997013751A1 (fr) * 1995-10-10 1997-04-17 Pfizer Inc. Indole-carbamates comme antagonistes de leukotriene
WO1998005637A1 (fr) * 1996-08-01 1998-02-12 Merckle Gmbh Acides acylpyrroldicarboxyliques et acides acylindoldicarboxyliques et leurs derives utilises en tant qu'inhibiteurs de la phospholipase a2 cytosolique
WO1998008818A1 (fr) * 1996-08-26 1998-03-05 Genetics Institute, Inc. Inhibiteurs des enzymes phospholipases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 121, no. 11, 12 September 1994, Columbus, Ohio, US; abstract no. 124872, XP002114445 *
CHEMICAL ABSTRACTS, vol. 76, no. 5, 31 January 1972, Columbus, Ohio, US; abstract no. 25103, XP002114446 *
CHEN, SI-FENG ET AL, ZHONGGUO YAOLI XUEBAO, vol. 15, no. 4, 1994, pages 299 - 302 *
R.D. DILLARD ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, 1996, WASHINGTON US, pages 5137 - 5158, XP002046055 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9504746B2 (en) 2004-09-17 2016-11-29 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide
US8969344B2 (en) 2005-08-02 2015-03-03 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US9006256B2 (en) 2006-05-18 2015-04-14 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition

Also Published As

Publication number Publication date
BR9908275A (pt) 2000-10-24
CN1310706A (zh) 2001-08-29
PL343007A1 (en) 2001-07-30
JP2002504541A (ja) 2002-02-12
KR20010041344A (ko) 2001-05-15
NZ506329A (en) 2004-01-30
EP1062205A2 (fr) 2000-12-27
CA2322162A1 (fr) 1999-09-02
HUP0101146A2 (hu) 2001-08-28
HRP20000551A2 (en) 2001-04-30
AU765427B2 (en) 2003-09-18
TR200002447T2 (tr) 2000-11-21
SK12752000A3 (sk) 2001-03-12
IL137719A0 (en) 2001-10-31
EA200000871A1 (ru) 2001-04-23
WO1999043654A2 (fr) 1999-09-02
ID26250A (id) 2000-12-07
EA003876B1 (ru) 2003-10-30
BG104779A (en) 2001-10-31
NO20004219L (no) 2000-10-23
HUP0101146A3 (en) 2001-11-28
AU2782599A (en) 1999-09-15
EE200000488A (et) 2002-02-15
NO20004219D0 (no) 2000-08-23
GEP20032920B (en) 2003-03-25

Similar Documents

Publication Publication Date Title
WO1999043654A3 (fr) Inhibiteurs d'enzymes phospholipases
WO1999005096A3 (fr) Inhibiteurs d'urokinase
CA2367017A1 (fr) Inhibiteurs de l'enzyme impdh
CA2340052A1 (fr) Compositions pharmaceutiques contenant des inhibiteurs de lipases et du chitosane
AU3664401A (en) Platelet adp receptor inhibitors
WO2004078712A3 (fr) Derives d'isoquinoline et leurs methodes d'utilisation
WO2001019829A3 (fr) Pyrazolopyrimidines en tant qu'agents therapeutiques
WO1999043651A3 (fr) Inhibiteurs d'enzymes phospholipases
ZA200108082B (en) Pharmaceutical compositions comprising dipeptidy peptidase IV inhibitors for the promotion of growth.
WO2000076971A3 (fr) Composes
WO2000007979A3 (fr) Composes et compositions pour l'administration de principes actifs
WO2000059902A3 (fr) Sulfonyles aryles faisant office d'inhibiteurs du facteur xa
PT915898E (pt) Forma i cristalina de claritromicina
MY133996A (en) Compounds for the treatment of ischemia
WO2002044183A3 (fr) Composes et leurs utilisations
AP9901478A0 (en) Compounds for the treatment of ischemia.
WO1997046207A3 (fr) Derives aromatiques heterocycliques utilises comme inhibiteurs enzymatiques
WO2000066104A3 (fr) Composes inhibant ace-2 et leurs procedes d'utilisation
HUP0101793A3 (en) Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
WO2003065987A3 (fr) Inhibiteurs de granzyme b
WO2001081316A3 (fr) Inhibiteurs de phenyle farnesyltransferase substitues
WO2003053971A8 (fr) Antiviraux a base de pyridoquinoxaline
WO2001091738A3 (fr) Inhibiteurs naaladase utilises pour traiter la sclerose laterale amyotrophique
AU1597201A (en) Pyrrolecarbonylimino derivatives as naaladase inhibitors
AU3864000A (en) Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99805157.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 137719

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1999908378

Country of ref document: EP

Ref document number: 1200000703

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 506329

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 27825/99

Country of ref document: AU

Ref document number: 2000/02447

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 12752000

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2322162

Country of ref document: CA

Ref document number: 2322162

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P20000551A

Country of ref document: HR

Ref document number: PA/a/2000/008292

Country of ref document: MX

Ref document number: IN/PCT/2000/254/KOL

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2000 533412

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2000-3115

Country of ref document: CZ

Ref document number: 1020007009457

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200000871

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1999908378

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-3115

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007009457

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 27825/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1020007009457

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2000-3115

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1999908378

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载